spacer
The Healthcare Sales & Marketing Network celebrates 25 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  PARP inhibitor 

 HSMN NewsFeed - 8 Dec 2022
Dantari Debuts with $47 Million Series A to Advance Best-in-Class Targeted Medicines for Solid Tumors
Biopharmaceuticals Oncology Venture Capital
 HSMN NewsFeed - 11 Feb 2021
Cyteir Therapeutics Secures $80 Million in Series C Financing to Advance Clinical Trials of Lead RAD51 Program
Biopharmaceuticals Oncology Venture Capital
 HSMN NewsFeed - 2 Mar 2020
Primmune Therapeutics Raises $7 Million Seed Financing to Develop Novel Oral TLR7 Immunotherapies for Cancer and Acute Viral Diseases
Biopharmaceuticals Venture Capital Personnel
 HSMN NewsFeed - 10 Jan 2020
Theragnostics Expands Team with Significant Appointments
Biopharmaceuticals Oncology Radiology Personnel
 HSMN NewsFeed - 15 Oct 2019
Cyteir Therapeutics Secures Additional $40.2 Million in Its Series B Financing and Doses First Patient in Phase 1/2 Study of First-in-Class RAD51 Inhibitor
Biopharmaceuticals Oncology Venture Capital Personnel
 HSMN NewsFeed - 19 Nov 2018
Merck KGaA, Darmstadt, Germany, and Pfizer Provide Update on Avelumab in Platinum-Resistant/Refractory Ovarian Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 22 Aug 2018
Sierra Oncology Obtains Debt Facility from Silicon Valley Bank to Acquire and Advance Momelotinib
Biopharmaceuticals Oncology Venture Capital
 HSMN NewsFeed - 22 Aug 2018
Sierra Oncology Acquires Momelotinib, an Investigational Janus Kinase (JAK) 1/2 and Activin Receptor Type 1 (ACVR1) Inhibitor for Myelofibrosis, from Gilead Sciences
Biopharmaceuticals Oncology Acquisitions
 HSMN NewsFeed - 24 May 2018
Curis Expands Senior Management Expertise with Appointment of Robert Martell, M.D., Ph.D., as Head of Research and Development
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 8 Mar 2018
Cyteir Therapeutics Secures $29 Million Series B to Advance Novel, Molecularly Targeted Therapies for Cancer and Autoimmune Diseases
Biopharmaceuticals Oncology Venture Capital Personnel
 HSMN NewsFeed - 30 Mar 2017
Third Rock Ventures Launches Tango Therapeutics with $55 Million Series A Investment
Biopharmaceuticals Oncology Personnel Venture Capital
 HSMN NewsFeed - 17 Feb 2017
LYNPARZA(TM) (olaparib) Meets Primary Endpoint in Phase III Trial in BRCA-Mutated Metastatic Breast Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 20 Dec 2016
Foundation Medicine Receives FDA Approval of FoundationFocus(TM) CDxBRCA as a Companion Diagnostic for Rubraca(TM) (rucaparib) for the Treatment of Women with Ovarian Cancer
Diagnostics Oncology FDA
 HSMN NewsFeed - 7 Nov 2016
Myriad Will Seek Japanese Regulatory Approval for BRACAnalysis CDx(R)
Diagnostics Oncology Regulatory
 HSMN NewsFeed - 22 Aug 2016
Pfizer to Acquire Medivation
Biopharmaceuticals Oncology Mergers & Acquisitions
 HSMN NewsFeed - 6 Apr 2016
Janssen Enters Worldwide Collaboration and License Agreement with TESARO, Inc., for Niraparib in Prostate Cancer
Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 18 Mar 2016
The Myriad myRisk(R) Hereditary Cancer Test Identifies 60 Percent More Deleterious Mutations in Patients with Endometrial Cancer
Diagnostics Oncology Personalized Medicine
 HSMN NewsFeed - 20 Jul 2015
BioMarin Provides Program Update for Talazoparib in Metastatic Breast Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 8 Jan 2015
Myriad Obtains CE Mark for Tumor BRACAnalysis CDx(TM) and Launches Test in Europe as Companion Diagnostic for PARP Inhibitors
Diagnostics Oncology Regulatory
 HSMN NewsFeed - 24 Oct 2014
Myriad Establishes Tumor BRACAnalysis CDx(TM) Laboratory in Europe
Diagnostics Oncology
 HSMN NewsFeed - 4 Feb 2010
BioMarin to Acquire LEAD Therapeutics
Biopharmaceuticals Mergers & Acquisitions Oncology
 HSMN NewsFeed - 1 Dec 2009
Canaan Partners Appoints Tim Shannon, M.D. as Venture Partner
Venture Capital Personnel
 HSMN NewsFeed - 8 Apr 2008
Inotek Focuses Resources on Clinical Programs, Adds to Executive Management Team and Consolidates Operations in Massachusetts
Biopharmaceuticals Personnel
 HSMN NewsFeed - 25 Sep 2007
BiPar Expands Management Team to Advance Lead PARP Inhibitor Product Candidate Into Phase 2 Trials for Cancer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 23 Aug 2007
Inotek Pharmaceuticals Secures $19 million Financing
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 19 Jun 2007
Myriad Genetics Collaborates With AstraZeneca on Phase 2 Trials
Biopharmaceuticals Oncology
 HSMN NewsFeed - 14 Feb 2007
Inotek Pharmaceuticals Announces Additions to its Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 9 Mar 2006
Inotek Pharmaceuticals hires Emma Reeve as Chief Financial Officer
Biopharmaceuticals Personnel
Return to NewsFeed  

 Additional items found! 3

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 3 additional stories matching:
PARP inhibitor
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.